Meditemp

Varicoceles Infertility Treatment

Health Tech & Life Sciences
Acquired by Generex Biotechnology Corporation
Acquired Haifa, Israel Founded 2007
Last updated 2026-06-18
Total raised
Stage
Acquired
Founded
2007
Headcount
6
HQ
Haifa, Israel
Sector
Health Tech & Life Sciences

About

MediTemp has developed a cooling device designed to improve sperm quality in men who are infertile due to varicoceles. The company's first product is Varicure, a compact and portable device thatfacilitates localized cooling of the testicular area with the aim to obviate male infertility due to poor semen quality. Varicure offers a conservative, safe, economic, and effective first-line therapy option to restore male fertility.

Q&A

What is Meditemp's primary product?
Meditemp's primary product is Varicure, a compact and portable cooling device designed to improve sperm quality in men infertile due to varicoceles.
When was Meditemp acquired and by whom?
Meditemp was acquired by Generex Biotechnology Corporation in October 2015.
What is Meditemp's current operational status?
Meditemp is currently inactive due to its acquisition by Generex Biotechnology Corporation in October 2015.
Where is Meditemp's headquarters located?
Meditemp's headquarters is in Haifa, Israel.
What sector does Meditemp operate in?
Meditemp operates in the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Medical Treatment & Therapeutics.
Does Meditemp hold any patents?
Yes, Meditemp holds one patent.
Who is the CEO of Meditemp?
Jacob Dagan is the CEO of Meditemp.

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesMedical Treatment & Therapeutics
Target customers
Healthcare & Life SciencesHealthcareProviders
Business model
B2B

Highlights

1 Patents

Tags

non-invasivemedical-devicestreatments
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

Identifiers & details

Founded2007-1
Employees (exact)6
OfficesOakland
Status reasonAcquired (Inactive) by Generex Biotechnology Corporation on Oct 2015 - closed due to acquisition

Acquisitions & public offerings

Acquired by Generex Biotechnology Corporation 2015-10

Radar intelligence

Patents

EPO2